Evidence of a chemopreventive effect of progestin unrelated to ovulation on reproductive tract cancers in the egg-laying hen

Cancer Prevention Research

Volumn 6, Issue 12, 2013, Pages 1283-1292

  Rodriguez, Gustavo C ^a   Barnes, H John ^b   Anderson, Kenneth E ^b   Whitaker, Regina S ^c   Berchuck, Andrew ^c   Petitte, James N ^b   Lancaster, Johnathan M ^d   Wenham, Robert M ^d   Turbov, Jane M ^a   Day, Roger ^e   Maxwell, G Larry ^f   Carver, Donna K ^b  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^f BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLECALCIFEROL; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALORIC INTAKE; CALORIC RESTRICTION; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER PREVENTION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DIET THERAPY; EGG LAYING; EGG PRODUCTION; FEMALE; FOOD INTAKE; HEN; NONHUMAN; OVARY CANCER; OVULATION; PRIORITY JOURNAL; UTERINE TUBE TUMOR;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHICKENS; DIETARY SUPPLEMENTS; EGGS; FEMALE; OVARIAN NEOPLASMS; OVIPOSITION; OVULATION; PROGESTINS; VITAMIN D;

EID: 84890452652     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-12-0426     Document Type: Article

References (39)

1. American Cancer Society. Cancer Facts and Figures 2005. Atlanta: American Cancer Society; 2005.
2. Wu ML, Whittemore AS, Paffenbarger RS Jr, Sarles DL, Kampert JB, Grosser S, et al. Personal and environmental characteristics related to epithelial ovarian cancer. I. Reproductive and menstrual events and oral contraceptive use. Am J Epidemiol 1988;128:1216-27.
3. Greene MH, Clark JW, Blayney DW. The epidemiology of ovarian cancer. Semin Oncol 1984;11:209-26.
4. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 U.S. case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992;136:1212-20.
5. Casagrande JT, Louie EW, Pike MC, Roy S, Ross RK, Henderson BE. "Incessant ovulation" and ovarian cancer. Lancet 1979;2:170-3.
6. Rodriguez GC, Walmer DK, Cline M, Krigman H, Lessey BA, Whitaker RS, et al. Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis? J Soc Gynecol Investig 1998;5:271-6.
7. Rodriguez GC, Nagarsheth NP, Lee KL, Bentley RC, Walmer DK, Cline M, et al. Progestin-induced apoptosis in the Macaque ovarian epithelium: differential regulation of transforming growth factor-beta. J Natl Cancer Inst 2002;94:50-60.
8. Reiss M. Transforming growth factor-beta and cancer: a love-hate relationship? Oncol Res 1997;9:447-57.
9. Lefkowitz ES, Garland CF. Sunlight, vitamin D, and ovarian cancer mortality rates in US women. Int J Epidemiol 1994;23:1133-6.
10. Salazar-Martinez E, Lazcano-Ponce EC, Gonzalez Lira-Lira G, Escudero-De los Rios P, Hernandez-Avila M. Nutritional determinants of epithelial ovarian cancer risk: a case-control study in Mexico. Oncology 2002;63:151-7.
11. Zhang X, Jiang F, Li P, Li C, Ma Q, Nicosia SV, et al. Growth suppression of ovarian cancer xenografts in nude mice by vitamin D analogue EB1089. Clin Cancer Res 2005;11:323-8.
12. Jiang F, Bao J, Li P, Nicosia SV, Bai W. Induction of ovarian cancer cell apoptosis by 1,25-dihydroxyvitamin D3 through the down-regulation of telomerase. J Biol Chem 2004;279:53213-21.
13. Anderson KE. Final Report of the Thirty Second North Carolina Layer Performance and Management Test. North Carolina Cooperative Extension Service [Internet]. 1998 [cited 1998 Jul]. Available from: http://www.ces.ncsu.edu/ depts/poulsci/tech-manuals/layer-reports/32-final-report.pdf.
14. Dunn IC, Sharp PJ. The effect of photoperiodic history on egg laying in dwarf broiler hens. Poult Sci 1992;71:2090-8.
15. National Research Council (U.S.), Subcommittee on Poultry Nutrition. Nutrient requirements of poultry. Ninth revised ed., 1994.
16. Nutrient requirements of domestic animals: A series. Washington, DC: National Academy Press; 2004. p. 176.
17. Gonzalez Bosquet J, Peedicayil A, Maguire J, Chien J, Rodriguez GC, Whitaker R, et al. Comparison of gene expression patterns between avian and human ovarian cancers. Gynecol Oncol 2011;120:256-64.
18. Fredrickson TN. Ovarian tumors of the hen. Environ Health Perspect 1987;73:35-51.
19. Carver DK, Barnes HJ, Anderson KE, Petitte JN, Whitaker R, Berchuck A, et al. Reduction of ovarian and oviductal cancers in calorie-restricted laying chickens. Cancer Prev Res 2011;4:562-7.
20. Trevino LS, Buckles EL, Johnson PA. Oral contraceptives decrease the prevalence of ovarian cancer in the hen. Cancer Prev Res 2012;5:343-9.
21. Barnes MN, Berry WD, Straughn JM, Kirby TO, Leath CA, Huh WK, et al. A pilot study of ovarian cancer chemoprevention using medroxyprogesterone acetate in an avian model of spontaneous ovarian carcinogenesis. Gynecol Oncol 2002;87:57-63.
22. Vieth R. The pharmacology of vitamin D, including fortification strategies. In: Feldman D, Pike JW, Glorieux FH, editors. Vitamin D. 2nd ed. Burlington, MA: Elsevier/Academic Press; 2005. p. 995-1015.
23. Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst 2002;94:32-8.
24. Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998;90:1774-86.
25. Glasier A. Contraception. In: DeGroot LJ, Jameson JL, et al., editors. Endocrinology. 6th ed. Philadelphia, PA: W.B. Saunders; 2010. p. 2417-27.
26. Stubblefield PG. Contraception. In: Copeland LJ, Jarrell JF, McGregor JA, editors. Textbook of gynecology. Philadelphia, PA: W.B. Saunders; 1993. p. 156-88.
27. Landgren BM. Mechanism of action of gestagens. Int J Gynecol Obstet 1990;32:95-110.
28. Whiteman DC, Siskind V, Purdie DM, Green AC. Timing of pregnancy and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2003;12:42-6.
29. Rostgaard K, Wohlfahrt J, Andersen PK, Hjalgrim H, Frisch M, Westergaard T, et al. Does pregnancy induce the shedding of premalignant ovarian cells? Epidemiology 2003;14:168-73.
30. Hunn J, Rodriguez G. Ovarian cancer: etiology, risk factors, and epidemiology. Clin Obstet Gynecol 2012;55:3- 23.
31. Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, et al. The tubal fi mbria is a preferred site for early adenocarcinomain women with familial ovarian cancer syndrome. Am J Surg Pathol 2006;30:230-6.
32. Lee Y, Medeiros F, Kindelberger D, Callahan MJ, Muto MG, Crum CP. Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer. Adv Anat Pathol 2006;13:1-7.
33. Piek JM, Kenemans P, Verheijen RH. Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its cause. Am J Obstet Gynecol 2004;191:718-32.
34. Crum CP, Drapkin R, Kindelberger D, Medeiros F, Miron A, Lee Y. Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res 2007;5:35-44.
35. Roh MH, Yassin Y, Miron A, Mehra KK, Mehrad M, Monte NM, et al. High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression. Mod Pathol 2010;23:1316-24.
36. Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship.AmJ Surg Pathol 2007;31:161-9.
37. Chivukula M, Niemeier LA, Edwards R, Nikiforova M, Mantha G, McManus K, et al. Carcinomas of distal fallopian tube and their association with tubal intraepithelial carcinoma: do they share a common "precursor" lesion? Loss of heterozygosity and immunohistochemical analysis using PAX 2, WT-1, and P53 markers. ISRNObstet Gynecol 2011;2011:858647.
38. Rodriguez GC, Rimel BJ, Watkin W, Turbov J, Barry C, Maxwell GL, et al. Progestin treatment induces apoptosis and modulates TGF-β in the uterine endometrium. Cancer Epidemiol Biomarkers Prev 2008;17:578-84.
39. Maxwell GL, Schildkraut JM, Calingaert B, Risinger JI, Dainty L, Marchbanks PA, et al. Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk. Gynecol Oncol 2006;103:535- 40.